Professional-grade financial intelligence

20M+ securities. Real-time data. Institutional insights.

Subscribe for $2

Trusted by professionals at Goldman Sachs, BlackRock, and JPMorgan

Overview
Profile
SciClone Pharmaceuticals (Holdings) Stock

SciClone Pharmaceuticals (Holdings) Stock 6600.HK

6600.HK
KYG4271B1023

Price

17.44
Today +/-
+0
Today %
+0 %

SciClone Pharmaceuticals (Holdings) stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the SciClone Pharmaceuticals (Holdings) stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the SciClone Pharmaceuticals (Holdings) stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the SciClone Pharmaceuticals (Holdings) stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze SciClone Pharmaceuticals (Holdings)'s market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

SciClone Pharmaceuticals (Holdings) Stock Price History

DateSciClone Pharmaceuticals (Holdings) Price
7/8/202417.44 undefined
7/5/202418.72 undefined

SciClone Pharmaceuticals (Holdings) Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SciClone Pharmaceuticals (Holdings), a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SciClone Pharmaceuticals (Holdings) from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SciClone Pharmaceuticals (Holdings)’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SciClone Pharmaceuticals (Holdings). Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SciClone Pharmaceuticals (Holdings)’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SciClone Pharmaceuticals (Holdings)’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SciClone Pharmaceuticals (Holdings)’s growth potential.

SciClone Pharmaceuticals (Holdings) Revenue, EBIT and net profit per share

DateSciClone Pharmaceuticals (Holdings) RevenueSciClone Pharmaceuticals (Holdings) EBITSciClone Pharmaceuticals (Holdings) Net Income
2025e4.24 B undefined1.45 B undefined1.38 B undefined
2024e3.67 B undefined1.28 B undefined1.21 B undefined
20233.16 B undefined1.26 B undefined1.12 B undefined
20222.75 B undefined1.11 B undefined855.36 M undefined
20212.52 B undefined1.04 B undefined923.36 M undefined
20201.92 B undefined807.44 M undefined753.7 M undefined
20191.71 B undefined657.35 M undefined614.6 M undefined
20181.41 B undefined529.7 M undefined535.08 M undefined
20171.21 B undefined228.28 M undefined19.58 M undefined

SciClone Pharmaceuticals (Holdings) Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
DIV. ()
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
20172018201920202021202220232024e2025e
1.211.411.711.922.522.753.163.674.24
-16.1721.3112.3031.289.1714.7716.3515.42
85.0778.4876.9377.6976.7775.3074.6864.1855.61
1.031.111.311.491.932.072.3600
0.020.540.610.750.920.861.121.211.38
-2,715.7914.7722.6422.58-7.3731.117.9414.21
-----0.350.390.540.62
00000011.4338.4614.81
677.87677.87677.87559.41695.36708.14650.4300
---------
Details

Keystats

ⓘ

Revenue and Growth

The SciClone Pharmaceuticals (Holdings) Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the SciClone Pharmaceuticals (Holdings) is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (B)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (k)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (B)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (B)
LONG-T. LIAB. (B)
DEFERRED TAXES (M)
OTHER LIAB. (k)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
2017201820192020202120222023
             
0.610.281.041.192.191.872.22
351.35603.17362.9324.79546.51780.96867.95
00000025.14
143.8145.4140.2171.59174.66140.56308.29
36.7522.625.67223.5490.21804.4422.44
1.141.061.571.9133.63.45
47.7852.4435.114.2629.8828.6339.42
22.6635.1662.46288.29420.97143.1110.64
0000000
127.07143.47169.25652.69606.1542.24396.04
0000000
87.149.396.9918.496.685.957.05
0.280.240.270.971.060.720.55
1.431.31.852.884.064.324
             
000192232237216
00001.731.711.01
1.011.041.480.10.311.011.99
-72.93-15.3912.1921.35-13.69196.08206.1
18.5119.3437.02190.27293.9472.3753.77
0.961.041.530.312.322.993.27
38.2552.5866.0557.55126.92102.72859.69
63.0655.6565.2481.2192.88138.79153.12
324.199.89155.85459.62343.04219.34295.47
0000000
19.1422.2119.47789.39393.93430.5913.06
0.440.230.311.390.960.891.32
0.020.020.011.170.770.420.02
2.984.946.249.2614.9814.5716.96
579800815194188205208
0.020.020.011.180.790.440.04
0.470.250.322.571.751.331.36
1.431.31.852.884.064.324.62
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of SciClone Pharmaceuticals (Holdings) provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand SciClone Pharmaceuticals (Holdings)'s financial health and stability.

Assets

SciClone Pharmaceuticals (Holdings)'s assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that SciClone Pharmaceuticals (Holdings) must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of SciClone Pharmaceuticals (Holdings) after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into SciClone Pharmaceuticals (Holdings)'s financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (B)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (B)
NET CHANGE IN EQUITY (B)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (B)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
201720182019202020212022
0.260.50.660.821.030.94
343536113107118
000000
-178-375313-53-230-319
361120104126443
111214746
12182253714467
0.150.171.030.981.031.18
-10-24-32-469-190-196
-4174-152-670-126-1,025
6199-119-20164-829
000000
-0.02-0.02-0.022.1-0.79-0.45
-0.45000.031.73-0.02
-476-542-234-53115-670
--518.00-211.00-2,183.00-3.00-
0000-827-205
-0.31-0.210.640.21.01-0.46
143.1142.67998.98511.6838.64987.44
000000

SciClone Pharmaceuticals (Holdings) stock margins

The SciClone Pharmaceuticals (Holdings) margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SciClone Pharmaceuticals (Holdings). The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SciClone Pharmaceuticals (Holdings).

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SciClone Pharmaceuticals (Holdings)'s sales revenue. A higher gross margin percentage indicates that the SciClone Pharmaceuticals (Holdings) retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SciClone Pharmaceuticals (Holdings)'s earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SciClone Pharmaceuticals (Holdings)'s total revenue generated. When comparing the revenue margin year over year, investors can gauge the SciClone Pharmaceuticals (Holdings)'s growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SciClone Pharmaceuticals (Holdings). Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SciClone Pharmaceuticals (Holdings)'s financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SciClone Pharmaceuticals (Holdings) Margin History

SciClone Pharmaceuticals (Holdings) Gross marginSciClone Pharmaceuticals (Holdings) Profit marginSciClone Pharmaceuticals (Holdings) EBIT marginSciClone Pharmaceuticals (Holdings) Profit margin
2025e74.67 %34.22 %32.62 %
2024e74.67 %34.84 %32.98 %
202374.67 %39.86 %35.55 %
202275.3 %40.24 %31.11 %
202176.75 %41.32 %36.66 %
202077.69 %42.09 %39.28 %
201976.98 %38.49 %35.98 %
201878.49 %37.6 %37.98 %
201785.06 %18.82 %1.61 %

SciClone Pharmaceuticals (Holdings) Stock Sales Revenue, EBIT, Earnings per Share

The SciClone Pharmaceuticals (Holdings) earnings per share therefore indicates how much revenue SciClone Pharmaceuticals (Holdings) has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue SciClone Pharmaceuticals (Holdings) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates SciClone Pharmaceuticals (Holdings)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of SciClone Pharmaceuticals (Holdings)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating SciClone Pharmaceuticals (Holdings)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

SciClone Pharmaceuticals (Holdings) Revenue, EBIT and net profit per share

DateSciClone Pharmaceuticals (Holdings) Sales per ShareSciClone Pharmaceuticals (Holdings) EBIT per shareSciClone Pharmaceuticals (Holdings) Earnings per Share
2025e6.51 undefined0 undefined2.12 undefined
2024e5.64 undefined0 undefined1.86 undefined
20234.85 undefined1.93 undefined1.72 undefined
20223.88 undefined1.56 undefined1.21 undefined
20213.62 undefined1.5 undefined1.33 undefined
20203.43 undefined1.44 undefined1.35 undefined
20192.52 undefined0.97 undefined0.91 undefined
20182.08 undefined0.78 undefined0.79 undefined
20171.79 undefined0.34 undefined0.03 undefined

SciClone Pharmaceuticals (Holdings) business model

SciClone Pharmaceuticals (Holdings) is one of the most popular companies on Eulerpool.com.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

SciClone Pharmaceuticals (Holdings) Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

SciClone Pharmaceuticals (Holdings) historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

SciClone Pharmaceuticals (Holdings) shares outstanding

The number of shares was SciClone Pharmaceuticals (Holdings) in 2024 — This indicates how many shares 650.433 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue SciClone Pharmaceuticals (Holdings) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates SciClone Pharmaceuticals (Holdings)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of SciClone Pharmaceuticals (Holdings)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating SciClone Pharmaceuticals (Holdings)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

SciClone Pharmaceuticals (Holdings) dividend history and estimates

In 2024, SciClone Pharmaceuticals (Holdings) paid a dividend amounting to 0.54 undefined. Dividend means that SciClone Pharmaceuticals (Holdings) distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for SciClone Pharmaceuticals (Holdings) provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify SciClone Pharmaceuticals (Holdings)’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating SciClone Pharmaceuticals (Holdings)'s overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

SciClone Pharmaceuticals (Holdings) Dividend History

DateSciClone Pharmaceuticals (Holdings) Dividend
2025e0.62 undefined
2024e0.54 undefined
20230.39 undefined
20220.35 undefined

SciClone Pharmaceuticals (Holdings) dividend payout ratio

In 2024, SciClone Pharmaceuticals (Holdings) had a payout ratio of 28.98%. The payout ratio indicates the percentage of the company's profits that SciClone Pharmaceuticals (Holdings) distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for SciClone Pharmaceuticals (Holdings) represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for SciClone Pharmaceuticals (Holdings) could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate SciClone Pharmaceuticals (Holdings)'s payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

SciClone Pharmaceuticals (Holdings) Payout Ratio History

DateSciClone Pharmaceuticals (Holdings) Payout ratio
2025e28.98 %
2024e28.98 %
202328.98 %
202228.98 %
202128.98 %
202028.98 %
201928.98 %
201828.98 %
201728.98 %
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for SciClone Pharmaceuticals (Holdings).

SciClone Pharmaceuticals (Holdings) shareholders

%
Name
Stocks
Change
Date
29.99603 % GL Partners Capital Management Ltd195,104,060012/31/2023
7.29156 % Central Huijin Investment Ltd.47,426,727012/31/2023
1.84180 % Beijing Convergence Management Consulting LLP11,979,69007/3/2024
0.74204 % GF Fund Management Co., Ltd.4,826,500-143,0006/30/2024
0.66948 % UBS Asset Management (Americas), Inc.4,354,500726,0005/28/2024
0.58197 % Norges Bank Investment Management (NBIM)3,785,3563,785,3566/30/2024
0.49375 % Bosera Asset Management Co., Ltd.3,211,500-3,817,5006/30/2024
0.32832 % China Asset Management Co., Ltd.2,135,5002,135,5006/30/2024
0.28554 % APG Asset Management N.V.1,857,2781,857,27812/31/2023
0.14875 % American Century Investment Management, Inc.967,500-200,5007/31/2024
1
2
3
4
5
...
10

SciClone Pharmaceuticals (Holdings) Executives and Management Board

Mr. Hong Zhao

(58)
SciClone Pharmaceuticals (Holdings) President, Chief Executive Officer, Executive Director (since 2013)
Compensation 25.84 M

Dr. Daniel Vasella

(70)
SciClone Pharmaceuticals (Holdings) Non-Executive Director
Compensation 569,000

Dr. Ping Chen

(63)
SciClone Pharmaceuticals (Holdings) Independent Non-Executive Director
Compensation 569,000

Mr. Yushao Gu

(52)
SciClone Pharmaceuticals (Holdings) Independent Non-Executive Director
Compensation 569,000

Ms. Wendy Hayes

(52)
SciClone Pharmaceuticals (Holdings) Independent Non-Executive Director
Compensation 569,000
1
2
3
4

Most common questions regarding SciClone Pharmaceuticals (Holdings)

What is the P/E ratio of SciClone Pharmaceuticals (Holdings) 2025?

The SciClone Pharmaceuticals (Holdings) P/E ratio is 8.21.

What is the P/S ratio of SciClone Pharmaceuticals (Holdings) 2025?

The SciClone Pharmaceuticals (Holdings) P/S ratio is 2.68.

What is the Quality Investing of SciClone Pharmaceuticals (Holdings)?

The Quality Investing for SciClone Pharmaceuticals (Holdings) is 6/10.

What is the revenue of SciClone Pharmaceuticals (Holdings) 2025?

The expected SciClone Pharmaceuticals (Holdings) revenue is 4.24 B CNY.

How high is the profit of SciClone Pharmaceuticals (Holdings) 2025?

The expected SciClone Pharmaceuticals (Holdings) profit is 1.38 B CNY.

What is the business model of SciClone Pharmaceuticals (Holdings)

No history available for SciClone Pharmaceuticals (Holdings).

What is the SciClone Pharmaceuticals (Holdings) dividend?

SciClone Pharmaceuticals (Holdings) pays a dividend of 0.35 CNY distributed over payouts per year.

How often does SciClone Pharmaceuticals (Holdings) pay dividends?

The dividend cannot currently be calculated for SciClone Pharmaceuticals (Holdings) or the company does not pay out a dividend.

What is the SciClone Pharmaceuticals (Holdings) ISIN?

The ISIN of SciClone Pharmaceuticals (Holdings) is KYG4271B1023.

What is the SciClone Pharmaceuticals (Holdings) ticker?

The ticker of SciClone Pharmaceuticals (Holdings) is 6600.HK.

How much dividend does SciClone Pharmaceuticals (Holdings) pay?

Over the past 12 months, SciClone Pharmaceuticals (Holdings) paid a dividend of 0.39 CNY . This corresponds to a dividend yield of about 2.24 %. For the coming 12 months, SciClone Pharmaceuticals (Holdings) is expected to pay a dividend of 0.54 CNY.

What is the dividend yield of SciClone Pharmaceuticals (Holdings)?

The current dividend yield of SciClone Pharmaceuticals (Holdings) is 2.24 %.

When does SciClone Pharmaceuticals (Holdings) pay dividends?

SciClone Pharmaceuticals (Holdings) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SciClone Pharmaceuticals (Holdings)?

SciClone Pharmaceuticals (Holdings) paid dividends every year for the past 4 years.

What is the dividend of SciClone Pharmaceuticals (Holdings)?

For the upcoming 12 months, dividends amounting to 0.54 CNY are expected. This corresponds to a dividend yield of 3.09 %.

In which sector is SciClone Pharmaceuticals (Holdings) located?

SciClone Pharmaceuticals (Holdings) is assigned to the 'Health' sector.

Wann musste ich die Aktien von SciClone Pharmaceuticals (Holdings) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SciClone Pharmaceuticals (Holdings) from 6/28/2023 amounting to 0.39 CNY, you needed to have the stock in your portfolio before the ex-date on 6/2/2023.

When did SciClone Pharmaceuticals (Holdings) pay the last dividend?

The last dividend was paid out on 6/28/2023.

What was the dividend of SciClone Pharmaceuticals (Holdings) in the year 2024?

In the year 2024, SciClone Pharmaceuticals (Holdings) distributed 0.39 CNY as dividends.

In which currency does SciClone Pharmaceuticals (Holdings) pay out the dividend?

The dividends of SciClone Pharmaceuticals (Holdings) are distributed in CNY.

All fundamentals about SciClone Pharmaceuticals (Holdings)

Our stock analysis for SciClone Pharmaceuticals (Holdings) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SciClone Pharmaceuticals (Holdings) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.